Beta Blocker Interruption After Uncomplicated Myocardial Infarction
Status:
Recruiting
Trial end date:
2023-08-29
Target enrollment:
Participant gender:
Summary
ABYSS is a national, multicenter, randomised, open label trial using the PROBE study design,
that will evaluate the non-inferiority of the interruption of ΒB therapy after an
uncomplicated MI after six months or more of follow-up compared to the continuation of βB
evaluated by the primary endpoint or death, MI, Stroke and rehospitalization for others
cardiovascular reasons.
Phase:
Phase 4
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborators:
ACTION Institut de Cardiologie Pitié-Salpêtrière Hospital Paris, France Groupe Hospitalier Pitie-Salpetriere